Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

Published:2022-11 Issue: Volume:176 Page:181-188
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

de Nonneville Alexandre^ORCID,Houvenaeghel Gilles^ORCID,Cohen Monique,Sabiani Laura,Bannier Marie,Viret Frederic,Gonçalves Anthony,Bertucci François

Funder

Ligue Contre le Cancer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update;Wolff;J Clin Oncol,2018

2. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer;Schettini;NPJ Breast Cancer,2021

3. HER2-low breast cancer: pathological and clinical landscape;Tarantino;J Clin Oncol,2020

4. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials;Denkert;Lancet Oncol,2021

5. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer;Eggemann;Endocr Relat Cancer,2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women;Cancers;2024-09-12

2. HER2-Low Breast Cancer: Now and in the Future;Cancer Research and Treatment;2024-07-15

3. Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China;PeerJ;2024-05-29

4. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study;Scientific Reports;2024-05-23

5. The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study;Breast Cancer Research and Treatment;2024-05-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3